RBRC00858, B6;129S6-Bcl2l12/Irf3<tm1Ttg>/TtgRbrc

RBRC No. RBRC00858
Type Targeted MutationCartagena wks
Species Mus musculus
Strain name B6;129S6-Bcl2l12/Irf3<tm1Ttg>/TtgRbrc
Former Common name IRF-3 KO/B6; IRF-3 Knockout mice, C57BL/6J
H-2 Haplotype No Data
ES cell line CCE/EK.CCE [129S/SvEv-Gpi1]
Donor strain 129S6/SvEv via CCE ES cell line
Background strain C57BL/6JJcl
Appearance
1 Appearance black
Genotype No Data
Strain development Developed by Tadatsugu Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo. C57BL/6 semicongenic strain.
Strain description The Irf3 deficient mice were created by replacing a 2.2 kb region of Irf3 containing a putative transcription initiation site and the coding N-terminal region of the DNA binding domain. The analysis of MEFs demonstrated loss of Irf3 protein. Homozygous null mice are more susceptible to viral infection such as encephalomyocarditis virus and exhibit lower serum interferon levels in response to viral infection, indicating incapability of the mutant to respond against viral infection.
Colony maintenance Homozygote x Homozygote
Health Report
Gene Details
Promoter No Data
1 Symbol Bcl2l12
Symbol name BCL2-like 12 (proline rich)
Chromosome 7
Common name Bcl2-L12, Bcl-L12
Symbol description No Data
2 Symbol Irf3
Symbol name interferon regulatory factor 3
Chromosome 7
Common name C920001K05Rik, IRF-3
Symbol description No Data
Promoter mouse phosphoglycerate kinase promoter (PGK promoter)
3 Symbol neo
Symbol name neomycin resistance gene (E. coli)
Chromosome 7
Common name neo; neomycin;
Symbol description No Data
References Immunity. 2000 Oct;13(4):539-48.

Research applications Immunology and Inflammation Research
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE.
Additional information
1 Taniguchi Lab HP
2 Mouse of the Month May 2005
Genetic Background
3 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Sperm
Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months

Live
Live mouse :
BRC mice in Publications
Title Journal
(PMID)
Author
Interferon regulatory factor 3 is involved in Toll-like receptor 4 (TLR4)- and TLR3-induced IL-12p35 gene activation. Blood.107(3): 1078-84 (2006).(16219795)
Goriely S, Molle C, Nguyen M, Albarani V, Haddou NO, Lin R, De Wit D, Flamand V, Willems F, Goldman M.
Paramyxovirus Sendai virus V protein counteracts innate virus clearance through IRF-3 activation, but not via interferon, in mice. Virology.359(1): 82-91 (2007).(17027894)
Kiyotani K, Sakaguchi T, Kato A, Nagai Y, Yoshida T.
IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3. J Immunol.178(12): 7607-15 (2007).(17548596)
Molle C, Nguyen M, Flamand V, Renneson J, Trottein F, De Wit D, Willems F, Goldman M, Goriely S.
Double-stranded RNA induces pancreatic beta-cell apoptosis by activation of the toll-like receptor 3 and interferon regulatory factor 3 pathways. Diabetes.57(5): 1236-45 (2008).(18223009)
Dogusan Z, Garc a M, Flamez D, Alexopoulou L, Goldman M, Gysemans C, Mathieu C, Libert C, Eizirik DL, Rasschaert J.
Studies on the paramyxovirus accessory genes by reverse genetics in the Sendai virus-mouse system. Proc Jpn Acad Ser B Phys Biol Sci.84(10): 439-51 (2008).(19075516)
Sakaguchi T, Kato A, Kiyotani K, Yoshida T, Nagai Y.
Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. J Virol.83(15): 7629-40 (2009).(19474102)
Abe T, Kaname Y, Wen X, Tani H, Moriishi K, Uematsu S, Takeuchi O, Ishii KJ, Kawai T, Akira S, Matsuura Y.
Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci.29(31): 9839-49 (2009).(19657036)
Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, Harrington CA, Stenzel-Poore MP.
Critical role of the IFN-stimulated gene factor 3 complex in TLR-mediated IL-27p28 gene expression revealing a two-step activation process. J Immunol.184(4): 1784-92 (2010).(20083668)
Molle C, Goldman M, Goriely S.
Stimulator of IFN gene is critical for induction of IFN-beta during Chlamydia muridarum infection. J Immunol.184(5): 2551-60 (2010).(20107183)
Prantner D, Darville T, Nagarajan UM.
Induction and inhibition of type I interferon responses by distinct components of lymphocytic choriomeningitis virus. J Virol.84(18): 9452-62 (2010).(20592086)
Zhou S, Cerny AM, Zacharia A, Fitzgerald KA, Kurt-Jones EA, Finberg RW.
Interferon response factor 3 is essential for house dust mite-induced airway allergy. J Allergy Clin Immunol.126(4): 836-844.e13 (2010).(20673978)
Marichal T, Bedoret D, Mesnil C, Pichavant M, Goriely S, Trottein F, Cataldo D, Goldman M, Lekeux P, Bureau F, Desmet CJ.
Viral induction of Zac1b through TLR3- and IRF3-dependent pathways. Mol Immunol.48(1-3): 119-27 (2010).(20947170)
Warz e B, Mesnil C, Hober D, Caloone D, Pirottin D, Garigliany MM, Desmecht D, Drion PV, Journot L, Lekeux P, Bureau F, Desmet CJ.
The role of TBK1 and IKK in the expression and activation of Pellino 1. Biochem J.434(3): 537-48 (2011).(21204785)
Smith H, Liu XY, Dai L, Goh ET, Chan AT, Xi J, Seh CC, Qureshi IA, Lescar J, Ruedl C, Gourlay R, Morton S, Hough J, McIver EG, Cohen P, Cheung PC.
A conventional protein kinase C inhibitor targeting IRF-3-dependent genes differentially regulates IL-12 family members. Mol Immunol. (2011).(21550664)
Johnson J, Molle C, Aksoy E, Goldman M, Goriely S, Willems F.
Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci.31(23): 8456-63 (2011).(21653850)
Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, Stenzel-Poore MP.
IRF3 protects from uterine horn pathology during Chlamydia muridarum genital infection in mice. Infect Immun. (2011).(21788382)
Prantner D, Sikes JD, Hennings L, Savenka AV, Basnakian AG, Nagarajan UM.
Differential impact of interferon regulatory factor 7 in the initiation of the type I interferon response in the LCMV infected CNS versus the periphery. J Virol. (2012).(22514347)
Christensen JE, Fenger C, Issazadeh-Navikas S, Krug A, Liljestr m P, Goriely S, Paludan SR, Finsen B, Christensen JP, Thomsen AR.
IRF3 deficiency leads to IL-17-mediated liver ischemia-reperfusion injury. Hepatology. (2012).(22911673)
Loi P, Yuan Q, Torres D, Delbauve S, Laute MA, Lalmand MC, P tein M, Goriely S, Goldman M, Flamand V.
Interferon regulatory factor 3 controls interleukin-17 expression in CD8 T lymphocytes. Proc Natl Acad Sci U S A.110(34): E3189-97 (2013).(23918362)
Ysebrant de Lendonck L, Tonon S, Nguyen M, Vandevenne P, Welsby I, Martinet V, Molle C, Charbonnier LM, Leo O, Goriely S.
Interferon regulatory factor 3 protects against adverse neo-intima formation. Cardiovasc Res. (2014).(24596398)
Zhang SM, Zhu LH, Li ZZ, Wang PX, Chen HZ, Guan HJ, Jiang DS, Chen K, Zhang XF, Tian S, Yang D, Zhang XD, Li H.
IFN Regulatory Factor 3 Potentiates Emphysematous Aggravation by Lipopolysaccharide. J. Immunol.198(9): 3637-3649 (2017).(28363903)
Ishii T, Hosoki K, Nikura Y, Yamashita N, Nagase T, Yamashita N.

RBRC00915, C.Cg-Irf9<tm1Ttg>/TtgRbrc

RBRC No. RBRC00915
Type Targeted Mutation CongenicCartagena wks
Species Mus musculus
Strain name C.Cg-Irf9<tm1Ttg>/TtgRbrc
Former Common name IRF-9 KO/BALB/c; BALB/cAJcl-Isgf3g<tm1>, IRF-9 Knockout mouse, BALB/c
H-2 Haplotype No Data
ES cell line TT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1]
Donor strain (C57BL/6 x CBA)F1 via TT2 EC cell line
Background strain BALB/cAJcl
Appearance
1 Appearance albino
Genotype No Data
Strain development Developed by Tadatsugu Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo. RBRC00915: Backcrossed to BALB/c (N8 generations), RBRC00916: Backcrossed to C57BL/6J (over N13 generations).
Strain description IRF-9 gene knockout mice. Homozygous mutant mice exhibit lower serum interferon levels in response to viral infection. BALB/c background (RBRC00915), C57BL/6 background (RBRC00916).
Colony maintenance Homozygote x Homozygote
Health Report
Gene Details
Promoter No Data
1 Symbol Irf9
Symbol name interferon regulatory factor 9
Chromosome 14
Common name Irf-9, p48, Isgf3g
Symbol description No Data
Promoter mouse phosphoglycerate kinase promoter (PGK promoter)
2 Symbol neo
Symbol name neomycin resistance gene (E. coli)
Chromosome 14
Common name neo; neomycin;
Symbol description No Data
References Genes Cells. 1996 Jan;1(1):115-24.

Research applications Immunology and Inflammation Research
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE.
Additional information
1 Taniguchi Lab HP
2 Mouse of the Month May 2005
3 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months
BRC mice in Publications
Title Journal
(PMID)
Author
IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest.118(4): 1417-26 (2008).(18340381)
Thibault DL, Chu AD, Graham KL, Balboni I, Lee LY, Kohlmoos C, Landrigan A, Higgins JP, Tibshirani R, Utz PJ.
Type I interferons regulate eomesodermin expression and the development of unconventional memory CD8(+) T cells. Nat. Commun. (2015).(25953241)
Martinet V1, Tonon S1, Torres D1, Azouz A1, Nguyen M1, Kohler A1, Flamand V1, Mao CA2, Klein WH2, Leo O1, Goriely S1.

RBRC00916, B6.Cg-Irf9<tm1Ttg>/TtgRbrc

RBRC No. RBRC00916
Type Targeted MutationCartagena wks
Species Mus musculus
Strain name B6.Cg-Irf9<tm1Ttg>/TtgRbrc
Former Common name IRF-9 KO/C57BL/6J ; p48<-/->; IRF-9<-/->, IRF-9 Knockout mouse, C57BL/6J
H-2 Haplotype No Data
ES cell line TT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1]
Donor strain (C57BL/6 x CBA)F1 via TT2 EC cell line
Background strain C57BL/6JJcl
Appearance
1 Appearance black
Genotype No Data
Strain development Developed by Tadatsugu Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo. RBRC00915: Backcrossed to BALB/c (N8 generations), RBRC00916: Backcrossed to C57BL/6J (over N13 generations).
Strain description IRF-9 gene knockout mice. Homozygous mutant mice exhibit lower serum interferon levels in response to viral infection. BALB/c background (RBRC00915), C57BL/6 background (RBRC00916).
Colony maintenance Homozygote x Homozygote
Health Report
Gene Details
Promoter No Data
1 Symbol Irf9
Symbol name interferon regulatory factor 9
Chromosome 14
Common name Irf-9, p48
Symbol description No Data
Promoter mouse phosphoglycerate kinase promoter (PGK promoter)
2 Symbol neo
Symbol name neomycin resistance gene (E. coli)
Chromosome 14
Common name neo; neomycin;
Symbol description No Data
References Genes Cells. 1996 Jan;1(1):115-24.

Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies.
Research applications Immunology and Inflammation Research
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE.
Additional information
1 Taniguchi Lab HP
2 Genetic Background
3 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Live
Live mouse :
BRC mice in Publications
Title Journal
(PMID)
Author
The type I interferon-alpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9. J Neurosci.30(3): 1149-57 (2010).(20089923)
Hofer MJ, Li W, Lim SL, Campbell IL.
MICE DEFICIENT FOR STAT1 BUT NOT STAT2 OR IRF9 DEVELOP A LETHAL CD4+ T-CELL-MEDIATED DISEASE FOLLOWING INFECTION WITH LYMPHOCYTIC CHORIOMENINGITIS VIRUS. J Virol. (2012).(22496215)
Hofer MJ, Li W, Manders P, Terry R, Lim SL, King NJ, Campbell IL.
IRF7-DEPENDENT, TYPE I INTERFERON PRODUCTION INDUCES LETHAL IMMUNE-MEDIATED DISEASE IN STAT1 KO MICE INFECTED WITH LCMV. J Virol. (2014).(24760883)
Li W, Hofer MJ, Jung SR, Lim SL, Campbell IL.

RBRC01420, B6;129P2-Irf7<tm1Ttg>/TtgRbrc

RBRC No. RBRC01420
Type Targeted MutationCartagena wks
Species Mus musculus
Strain name B6;129P2-Irf7<tm1Ttg>/TtgRbrc
Former Common name IRF-7-KO, IRF7, IRF-7 knockout mice, C57BL/6J
H-2 Haplotype No Data
ES cell line E14.1 [129P2/OlaHsd]
Donor strain 129P2/OlaHsd via E14.1 ES cell line
Background strain C57BL/6J
Appearance
1 Appearance black
Genotype a/a
Strain development Developed by Kenya Honda and Tadatsugu Taniguchi, Graduate School of Medicine and Faculty of Medicine, University of Tokyo in 2001. The knockout construct was electroporated into E14 ES cells derived from 129P2/OlaHsd. C57BL/6 semicongenic strain.
Strain description IRF7 knockout mice. Exon 2 and 3 of Irf7 gene were replaced with a PGK-beta-geo cassette. Homozygous mutant mice are vulnerable to viral infection with a decreased serum interferon level.
Colony maintenance Homozygote x Homozygote
Health Report
Gene Details
Promoter No Data
1 Symbol neo
Symbol name neomycin resistance gene (E. coli)
Chromosome 7
Common name neo; neomycin;
Symbol description No Data
2 Symbol Irf7
Symbol name interferon regulatory factor 7
Chromosome 7
Common name No Data
Symbol description No Data
Promoter mouse phosphoglycerate kinase promoter (PGK promoter)
3 Symbol lacZ
Symbol name beta-galactosidase (E. coli)
Chromosome 7
Common name No Data
Symbol description E. coli beta galactosidase
References Nature. 2005 Apr 7;434(7034):772-7. Epub 2005 Mar 30.

Research applications Fluorescent Proteins/lacZ System
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
Additional information
1 Mouse of the Month May 2005
Genetic Background
2 Taniguchi Lab HP
3 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Sperm
Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months

Live
Live mouse :
BRC mice in Publications
Title Journal
(PMID)
Author
Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol.178(11): 6876-85 (2007).(17513736)
Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, Rifkin IR.
Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J Virol.83(10): 1167893 (2009).(19264779)
Kinpara S, Hasegawa A, Utsunomiya A, Nishitsuji H, Furukawa H, Masuda T, Kannagi M.
Innate killing of Leishmania donovani by macrophages of the splenic marginal zone requires IRF-7. PLoS Pathog.6(3): e1000813 (2010).(20300600)
Phillips R, Svensson M, Aziz N, Maroof A, Brown N, Beattie L, Signoret N, Kaye PM.
Type I interferon signaling contributes to chronic inflammation in a murine model of silicosis. Toxicol Sci.116(2): 682-92 (2010).(20513754)
Giordano G, van den Br le S, Lo Re S, Triqueneaux P, Uwambayinema F, Yakoub Y, Couillin I, Ryffel B, Michiels T, Renauld JC, Lison D, Huaux F.
Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system. J Immunol.185(2): 1258-64 (2010).(20562259)
Khorooshi R, Owens T.
Interferon regulatory factor 7 contributes to the control of Leishmania donovani in the mouse liver. Infect Immun.79(3): 1057-66 (2011).(21149596)
Beattie L, Phillips R, Brown N, Owens BM, Chauhan N, Dalton JE, Kaye PM.
IRF3 protects from uterine horn pathology during Chlamydia muridarum genital infection in mice. Infect Immun. (2011).(21788382)
Prantner D, Sikes JD, Hennings L, Savenka AV, Basnakian AG, Nagarajan UM.
Interferon regulatory factor-7 modulates experimental autoimmune encephalomyelitis in mice. J Neuroinflammation.8: 181 (2011).(22196084)
Salem M, Mony JT, Lobner M, Khorooshi R, Owens T.
Differential impact of interferon regulatory factor 7 in the initiation of the type I interferon response in the LCMV infected CNS versus the periphery. J Virol. (2012).(22514347)
Christensen JE, Fenger C, Issazadeh-Navikas S, Krug A, Liljestr m P, Goriely S, Paludan SR, Finsen B, Christensen JP, Thomsen AR.
Role of interferon regulatory factor 7 in T cell responses during acute lymphocytic choriomeningitis virus infection. J Virol.86(20): 11254-65 (2012).(22875973)
Zhou S, Cerny AM, Fitzgerald KA, Kurt-Jones EA, Finberg RW.
Interferon regulatory factor 7 (IRF7) is required for the optimal initial control but not subsequent clearance of lymphocytic choriomeningitis virus infection in mice. Virology.439(2): 152-62 (2013).(23490048)
Li W, Hofer MJ, No on AL, Manders P, Campbell IL.
Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance. Am J Physiol Endocrinol Metab.305(4): E485-95 (2013).(23695216)
Wang XA, Zhang R, Zhang S, Deng S, Jiang D, Zhong J, Yang L, Wang T, Hong S, Guo S, She ZG, Zhang XD, Li H.
IRF7-DEPENDENT, TYPE I INTERFERON PRODUCTION INDUCES LETHAL IMMUNE-MEDIATED DISEASE IN STAT1 KO MICE INFECTED WITH LCMV. J Virol. (2014).(24760883)
Li W, Hofer MJ, Jung SR, Lim SL, Campbell IL.
TLR9 and STING agonists synergistically induce innate and adaptive type II IFN. Eur J Immunol. (2014).(25529558)
Temizoz B, Kuroda E, Ohata K, Jonai N, Ozasa K, Kobiyama K, Aoshi T, Ishii KJ.
IRF7 inhibition prevents destructive innate immunity-A target for nonantibiotic therapy of bacterial infections. Sci Transl Med.8(336): 336ra59. (2016).(27122612)
Puthia M, Ambite I, Cafaro C, Butler D, Huang Y, Lutay N, Rydström G, Gullstrand B, Swaminathan B, Nadeem A, Nilsson B, Svanborg C.

RBRC05553, B6.129P2-Pmaip1<tm1Ttg>

RBRC No. RBRC05553
Type Targeted MutationCartagena
Species Mus musculus
Strain name B6.129P2-Pmaip1<tm1Ttg>
Former Common name B6-Noxa KO
H-2 Haplotype No Data
ES cell line E14.1 [129P2/OlaHsd]
Background strain C57BL/6JJcl
Appearance
1 Appearance No Data
Genotype No Data
Strain development Developed by Tsukasa Shibue and Tadatsugu Taniguchi, Graduate School of Medicine, University of Tokyo in 2003. E14.1 ES cell derived. The mutant mice were backcrossed to C57BL/6J.
Strain description Noxa (Pmaip1) gene knockout mice. A 2.4 kb genomic region including exons 1 and 2 of the Pmaip1 gene was replaced with a neomycin selection cassette. Homozygous mutant mice are resistant to X-ray irradiation-induced gastrointestinal death.
Colony maintenance Heterozygote x Wild-type [C57BL/6JJcl]
Health Report
Gene Details
Promoter No Data
1 Symbol neo
Symbol name neomycin resistance gene (E. coli)
Chromosome 18
Common name neo; neomycin;
Symbol description No Data
2 Symbol Pmaip1
Symbol name phorbol-12-myristate-13-acetate-induced protein 1
Chromosome 18
Common name No Data
Symbol description No Data
References

Research applications No Data
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE.
Additional information
1 Taniguchi Lab HP
2 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Sperm
Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months

RBRC05949, B6.129P2-Rbm3<tm1Ttg>

RBRC No. RBRC05949
Type Targeted MutationCartagena
Species Mus musculus
Strain name B6.129P2-Rbm3<tm1Ttg>
Former Common name B6-RBM3 KO, B6-Rbm3 KO
H-2 Haplotype No Data
ES cell line E14.1 [129P2/OlaHsd]
Background strain No Data
Appearance
1 Appearance No Data
Genotype No Data
Strain development Developed by Tadatsugu Taniguchi, Graduate School of Medicine, University of Tokyo in 2011. E14.1 ES cell derived. The mutant mice were backcrossed to C57BL/6J.
Strain description Rbm3 gene knockout mice. The region containing exon 4 and 5 and part of exons 3 and 6 of Rbm3 gene were replaced with a PGK-neo cassette. Homozygous and hemizygous mutant mice show no obvious abnormality.
Colony maintenance Homozygote (female) x Hemizygote (female) [or Crossing to C57BL/6JJcl]
Health Report
Gene Details
Promoter No Data
1 Symbol Rbm3
Symbol name RNA binding motif protein 3
Chromosome X
Common name No Data
Symbol description No Data
Promoter mouse phosphoglycerate kinase promoter (PGK promoter)
2 Symbol neo
Symbol name neomycin resistance gene (E. coli)
Chromosome X
Common name No Data
Symbol description No Data
References

Research applications No Data
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The RECIPIENT shall inform the DEPOSITOR about the purpose of the use of the BIOLOGICAL RESOURCE and shall limit the use within the scope of the purpose described in this Agreement. The RECIPIENT shall inform the DEPOSITOR about the results obtained by the use of the BIOLOGICAL RESOURCE.
Additional information
1 No Data
2 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Sperm
Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months

RBRC06240, B6.129P2-Hmgb1<tm1Ttg>

RBRC No. RBRC06240
Type Targeted MutationCartagena
Species Mus musculus
Strain name B6.129P2-Hmgb1<tm1Ttg>
Former Common name Hmgb1 cKO, B6-Hmgb1 floxed
H-2 Haplotype No Data
ES cell line E14.1 [129P2/OlaHsd]
Background strain No Data
Appearance
1 Appearance No Data
Genotype No Data
Strain development Developed by Hideyuki Yanai and Tadatsugu Taniguchi, Institute of Industrial Science, University of Tokyo and Nobuaki Yoshida, Institute of Medical Science, University of Tokyo in 2011. E14.1 ES cells were used. The mutant mice were backcrossed to C57BL/6.
Strain description Hmgb1 gene floxed mice. Exons 2 to 4 were flanked by loxP sites. Homozygous mutant mice are viable, but show weak fertility.
Colony maintenance Heterozygote x Wild-type [or Crossing to C57BL/6JJcl]
Health Report
Gene Details
Promoter No Data
1 Symbol Hmgb1
Symbol name high mobility group box 1
Chromosome 5
Common name No Data
Symbol description No Data
2 Symbol loxP
Symbol name phage P1 loxP
Chromosome 5
Common name No Data
Symbol description No Data
References

Research applications Cre/loxP system,
Immunology and Inflammation Research
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE.
Additional information
1 Mouse of the Month Jun 2014
2 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Sperm
Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months

Live
Live mouse :

RBRC10094, B6.Cg-Irf3<tm2.2Ttg>

RBRC No. RBRC10094
Type Targeted Mutation CongenicCartagena
Species Mus musculus
Strain name B6.Cg-Irf3<tm2.2Ttg>
Former Common name IRF3 KO
H-2 Haplotype No Data
ES cell line TT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1]
Background strain C57BL/6JJcl
Appearance
1 Appearance No Data
Genotype No Data
Strain description No Data
Health Report
Gene Details
Promoter No Data
1 Symbol Irf3
Symbol name interferon regulatory factor 3
Chromosome 7
Common name No Data
Symbol description No Data
2 Symbol loxP
Symbol name phage P1 loxP
Chromosome 7
Common name No Data
Symbol description No Data
References No Data

Research applications Cre/loxP system,
Immunology and Inflammation Research
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form.
Proc Natl Acad Sci USA. 2018 May 15, 115(20), 5253-5258.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR.
Additional information
1 No Data
2 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Frozen
Cryopreserved embryos : Within 1 month
Recovered litters from cryopreserved embryos : 2-4 months

Sperm
Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months

RBRC10095, B6.Cg-Irf3<tm2.1Ttg>

RBRC No. RBRC10095
Type Targeted Mutation CongenicCartagena
Species Mus musculus
Strain name B6.Cg-Irf3<tm2.1Ttg>
Former Common name IRF3-flox
H-2 Haplotype No Data
ES cell line TT2 [(C57BL/6NCrlj x CBA/JNCrlj)F1]
Background strain C57BL/6JJcl
Appearance
1 Appearance No Data
Genotype No Data
Strain description No Data
Health Report No Data
Gene Details
Promoter No Data
1 Symbol Frt
Symbol name yeast FRT (flippase recombination target) site
Chromosome 7
Common name No Data
Symbol description No Data
2 Symbol Irf3
Symbol name interferon regulatory factor 3
Chromosome 7
Common name No Data
Symbol description No Data
3 Symbol loxP
Symbol name phage P1 loxP
Chromosome 7
Common name No Data
Symbol description No Data
References No Data

Research applications Cre/loxP system,
FLP/frt system,
Immunology and Inflammation Research
Specific Term and Conditions The following terms and conditions will be requested by the DEPOSITOR.
Prior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form.
Proc Natl Acad Sci USA. 2018 May 15, 115(20), 5253-5258.
In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the Acc.No. CDB1028K and Web Site (www2.clst.riken.jp/arg/mutant%20mice%20list.html) is requested. The RECIPIENT must submit any and all copy of the publications using BIOLOGICAL RESOURCES to RIKEN Center for Life Sciences Technologies, Laboratories of Animal Resource development and Genetic Engineering (RIKEN CLST/LARGE) (mutant@cdb.riken.jp).
In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the first major literature is requested.
Additional information
1 No Data
2 Genotyping protocol <PCR>
Depositor Taniguchi, Tadatsugu (The University of Tokyo, Graduate School of Medicine) Taniguchi, Tadatsugu
Strain Status /
Availability
(Expected delivery)


Sperm
Cryopreserved sperm : Within 1 month
Recovered litters from cryopreserved sperm : 2-4 months